---
document_datetime: 2023-09-21 21:47:09
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nevirapine-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: nevirapine-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.0335023
conversion_datetime: 2025-12-22 13:06:47.359906
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Nevirapine Teva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0024               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 08/12/2021                                  |                                             | PL                               |           |
| IA/0023              | A.7 - Administrative change - Deletion of manufacturing sites                                    | 02/02/2021                                  | 29/09/2021                                  | Annex II and PL                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Medicinal product no longer authorised

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0022   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                    | 05/10/2020         | 29/09/2021   | SmPC, Annex II, Labelling and PL   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------|------------------------------------|
| IA/0021   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                     | 12/06/2019         | n/a          |                                    |
| IB/0020   | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                        | 29/03/2019         | n/a          | authorised                         |
| IB/0019   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                        | 21/02/2019         | n/a          | longer                             |
| IAIN/0018 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                    | 24/10/2018         | 17/10/2019   | SmPC                               |
| IA/0017   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer       | 28/06/2018         | n/a no       |                                    |
| IA/0016   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer       | 23/06/2017 product | n/a          |                                    |
| IAIN/0015 | B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer Medicinal | 12/06/2017         | n/a          |                                    |

<div style=\"page-break-after: always\"></div>

| IB/0014   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                     | 22/08/2016   | 24/03/2017    | SmPC, Labelling and PL authorised   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-------------------------------------|
| N/0012    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                 | 27/04/2016   | 24/03/2017    | PL                                  |
| IA/0013   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                    | 25/04/2016   | 24/03/2017    | Annex II and PL                     |
| T/0011    | Transfer of Marketing Authorisation fom Teva Pharma B.V. (Utrecht) and Teva B.V (Haarlem). Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                   | 07/10/2014   | 22/10/2014 no | SmPC, Labelling and PL longer       |
| R/0010    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                          | 26/06/2014   | 26/08/2014    | SmPC, Annex                         |
| IB/0009/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference Medicinal product | 03/04/2014   | 26/08/2014    | II and PL SmPC, Labelling and PL    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | longer authorised                |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| IAIN/0008 | B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition) 10/01/2014 no                                                                                                                                                                                                                                                                                                                                                                                                                         |                                  |
| IB/0007/G | This was an application for a group of variations. To include information on a class labelling for all antiretrovirals to revise section 4.4 and section 4.8 of the SmPC to include information regarding Autoimmune Disorders under Immune Reactivation Syndrome. The changes have also been reflected in the PL. ' The MAH also wishes to revise section 4.4 and 4.5 of the SmPC and section 2 of the PIL to include Granulocytopenia in line with the originator 11/10/2013 20/02/2014 Medicinal product                                                                                                                               | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | the MAH C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| IAIN/0006 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 04/06/2013 n/a authorised                              |
| IB/0005/G | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                       | 21/02/2013 20/02/2014 SmPC, Labelling and PL no longer |
| IB/0003   | Update of section 4.8 of the SmPC and section 4 of the PL in order to include the adverse drug reactions (\"Blood pressure increased\" and \"Blood phosphorus decreased\") and updated frequencies/frequency categories. Furthermore the MAH also made minor amendments to the SmPC to bring the texts in line with those of the innovator. The MAH has also taken this opportunity to update some details in the local contact list in the PL. In addition, a correction has been made to the SK Annex. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following 07/10/2011 Medicinal product | 25/05/2012 SmPC and PL                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |                                                 |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------------------------------------|
| IA/0004 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/09/2011 | n/a                                             |
| IB/0002 | To update sections 4.4 and 4.6 of the SmPC, and section 2 of the PL in order to give a better characterisation of the patient groups that are at greater risk of developing hepatotoxicity following evaluation of an analysis made by an expert panel. In addition, the MAH has also made minor amendments to the SmPC, labelling and PL to bring them in line with the reference product (sections 2, 4.2, 4.8, 4.9, 5.1, 5.2, 5.3). The MAH has taken this opportunity to include the new EMA acronym and new EMA web site address and to update the local contact list in the PL. Annex IIB has also been updated to remove the version number of the DDPS according to the procedural announcement from October 2010. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH Medicinal product | 07/01/2011 | n/a SmPC, Labelling and PL no longer authorised |

<div style=\"page-break-after: always\"></div>

| IA/0001   | To replace a manufacturing site regarding secondary packaging activities for the finished product (EU/1/09/598/001-4). IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site   | 15/12/2009   | n/a   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|

<!-- image -->